Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year ...

High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Democratic leaders assert the Emergency Medical Treatment and Labor Act (EMTALA) remains vital for emergency care, countering confusion from recent policy changes affecting abortion rights and patient ...

The recent approval of lenacapavir could change the way that clinicians approach both treating and preventing HIV in those at risk, as long as the treatment can get into their hands.

A teledermatology program in Georgia helped identify patients with skin lesions that warranted in-person follow-up with a physician.

Pharmacists are being asked to not only manage medications and side effects but also be fiscally responsible for the whole institution and its trickle-down effect on costs, said David Awad, PharmD, ...

Early circulating tumor DNA (ctDNA) changes predict survival in mismatch repair or microsatellite instability–high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with immune checkpoint ...

The recent approval of garadacimab can help to treat patients with hereditary angioedema (HAE) along with sebetralstat, which is awaiting FDA approval, explains Timothy Craig, DO, Penn State Health.

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.